Jensen 2013.

Study characteristics
Methods	Trial design: randomised, double‐blind, within‐participant study Trial registration number: EudraCT‐No. 2007‐003106‐99 Country, outpatient or hospital, date trial conducted: not reported Duration of trial participation: 3 weeks Inclusion criteria: · Mild‐to‐moderate AD according to Hanifin and Rajka criteria · Target lesion score of 3 to 8 (on a scale of 0‐12) for both right and left target lesions · Symmetric AD lesions (not differing > 1 point between the right and left sides) affecting the upper limbs by at least 10% Exclusion criteria: not reported Additional design details: none
Participants	Total number randomised: 30 sides treated (15 to apply the intervention and 15 to apply the comparator) Age: 21 to 45 years Sex: female n = 7, male n = 9 Ethnicity, duration of eczema: not reported Severity of eczema: mild‐to‐moderate Body site: upper limb Number of withdrawals: not reported Notes: none
Interventions	Run‐in details: not reported Intervention: pimecrolimus 1% cream used twice daily for 21 days · Concurrent treatment: not reported · Other key information: none Comparator: triamcinolone acetonide 0.1% cream used twice daily for 21 days · Concurrent treatment: not reported · Other key information: none Concurrent treatments received alongside both intervention and comparator: not reported Notes: none
Outcomes	· EASI · Pruritus
Notes	Funding source: not reported Declarations of interest: two authors had been supported by grants from a pharmaceutical company, Novartis, and one was a consultant. One was employed by Novartis. Novartis manufactures primecrolimus. Original language of publication: English Other: none